Pragmatic approaches to determine the exposures of drug metabolites in preclinical and clinical subjects in the MIST evaluation of the clinical development phase

Chemical Research in Toxicology

Volumn 27, Issue 4, 2014, Pages 601-610

  Haglund, Johanna ^a,b   Halldin, Magnus M ^a,c   Brunnström, Åsa ^a,b   Eklund, Göran ^a,b   Kautiainen, Antti ^a,b   Sandholm, Anna ^a,b   Iverson, Suzanne L ^a,d  

^a ASTRAZENECA R AND D   (Sweden)

^b MetaSafe AB Biovation Park Telge ^*  (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; CYTOCHROME P450 2D6;

ANALYTIC METHOD; ARTICLE; DOG; DRUG EXPOSURE; DRUG SAFETY; EVALUATION STUDY; FOOD AND DRUG ADMINISTRATION; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; RAT; ADVERSE DRUG REACTION; ANIMAL; AREA UNDER THE CURVE; CLINICAL TRIAL (TOPIC); DRUG SCREENING; METABOLISM; PHARMACOKINETICS; UNITED STATES;

ANIMALS; AREA UNDER CURVE; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 CYP2D6; DRUG EVALUATION, PRECLINICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PHARMACOKINETICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84899450420     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx400449z     Document Type: Article

References (47)

1. Baillie, T. A., Cayen, M. N., Fouda, H., Gerson, R. J., Green, J. D., Grossman, S. J., Klunk, L. J., LeBlanc, B., Perkins, D. G., and Shipley, L. A. (2002) Drug metabolites in safety testing Toxicol. Appl. Pharmacol. 182, 188-196
2. Smith, D. A. and Obach, R. S. (2005) Seeing through the Mist: Abundance versus percentage. Commentary on metabolites in safety testing Drug Metab. Dispos. 33, 1409-1417
3. Guengerich, F. P. (2006) Safety assessment of stable drug metabolites Chem. Res. Toxicol. 19, 1559-1560
4. Davis-Bruno, K. L. and Atrakchi, A. (2006) A regulatory perspective on issues and approaches in characterizing human metabolites Chem. Res. Toxicol. 19, 1561-1563
5. Humphreys, G. H. and Unger, S. E. (2006) Safety assessment of drug metabolites: Characterization of chemically stable metabolites Chem. Res. Toxicol. 19, 1564-1569
6. Smith, D. A. and Obach, R. S. (2006) Metabolites and safety: What are the concerns and how should we address them? Chem. Res. Toxicol. 19, 1570-1579
7. Naito, S., Furuta, S., Yoshida, T., Kitada, M., Fueki, O., Unno, T., Ohno, Y., Onodera, H., Kawamura, N., Kurokawa, M., Sagami, F., Shinoda, K., Nakazawa, T., and Yamazaki, T. (2007) Current opinion: Safety evaluation of drug metabolites in development of pharmaceuticals J. Toxicol. Sci. 32, 329-341
8. Guengerich, F. P. (2009) Introduction: Human metabolites in safety testing (MIST) issue Chem. Res. Toxicol. 22, 237-238
9. Anderson, S., Luffer-Atlas, D., and Knadler, M. P. (2009) Predicting circulating human metabolites: How good are we? Chem. Res. Toxicol. 22, 243-256
10. Powley, M. W., Frederick, C. B., Sistare, F. D., and DeGeorge, J. J. (2009) Safety assessment of drug metabolites: Implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s Chem. Res. Toxicol. 22, 257-268
11. Baillie, T. A. (2009) Approaches to the assessment of stable and chemically reactive drug metabolites in early clinical trials Chem. Res. Toxicol. 22, 263-266
12. Smith, D. A. and Obach, R. S. (2009) Metabolites in safety testing (MIST): Considerations of mechanisms of toxicity with dose, abundance, and duration of treatment Chem. Res. Toxicol. 22, 267-279
13. Leclercq, L., Cuyckens, F., Mannens, G. S., de Vries, R., Timmerman, P., and Evans, D. C. (2009) Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development Chem. Res. Toxicol. 22, 280-293
14. Espina, R., Yu, L., Wang, J., Tong, Z., Vashishtha, S., Talaat, R., Scatina, J., and Mutlib, A. (2009) Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: Implications in metabolites in safety testing Chem. Res. Toxicol. 22, 299-310
15. Vishwanathan, K., Babalola, K., Wang, J., Espina, R., Yu, L., Adedoyin, A., Talaat, R., Mutlib, A., and Scatina, J. (2009) Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: Addressing metabolites in safety testing (MIST) guidance without using radiolabelled compounds and chemically synthesized metabolite standards Chem. Res. Toxicol. 22, 311-322
16. Dalvie, D., Obach, R. S., Kang, P., Prakash, C., Loi, C.-M., Hurst, S., Nedderman, A., Goulet, L., Smith, E., Bu, H.-Z., and Smith, D. A. (2009) Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites Chem. Res. Toxicol. 22, 357-368
17. U.S. Food and Drug Administration (2008) Guidance for Industry: Safety Testing of Drug Metabolites. FDA, Rockville, MD.
18. International Conference on Harmonisation M3(R2) (2009) Guidance on Non-clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing authorization for Pharmaceuticals. ICH, Geneva, Switzerland.
19. International Conference on Harmonisation (2012) Questions & Answers (R2). ICH, Geneva, Switzerland.
20. Atrakchi, A. H. (2009) Interpretation and considerations on the safety evaluation of human drug metabolites Chem. Res. Toxicol. 22, 1217-1220
21. Nedderman, A. N. R. (2009) Metabolites in safety testing: metabolite identification strategies in discovery and development Biopharm. Drug Dispos. 30, 153-162
22. Yu, H., Bischoff, D., and Tweedie, D. (2010) Challenges and solutions to metabolites in safety testing: Impact of the international conference on harmonization M2(R2) guidance Expert Opin. Drug Metab. Toxicol. 6, 1539-1549
23. U.S. Food and Drug Administration (2010) Guidance for Industry: S9 Nonclinical Evaluation for Anticancer Pharmaceuticals. FDA, Rockville, MD.
24. U.S. Food and Drug Administration (2008) Guidance for Industry: S1C(R2) Dose Selection for Carcinogenicity Studies. FDA, Rockville, MD.
25. Gao, H., Deng, S., and Obach, R. S. (2010) A simple liquid chromatography-tandem mass spectrometry method to determine relative plasma exposures of drug metabolites across species for metabolite safety assessment Drug Metab. Dispos. 38, 2147-2156
26. Gao, H. and Obach, R. S. (2011) Addressing MIST (Metabolites in Safety Testing): Bioanalytical approaches to address metabolite exposure in humans and animals Curr. Drug Metab. 12, 578-586
27. Gao, H. and Obach, R. S. (2012) A Simple LC/MS/MS method to determine relative plasma exposures of drug metabolites across species for Metabolite Safety Assessments (MIST) Part 2: Application to unstable metabolites Drug Metab. Dispos. 40, 1290-1296
28. Ma, S., Li, Z., Lee, K.-J., and Chowdhury, S. K. (2010) Determination of exposure multiples of human metabolites for MIST assessment in preclinical safety species without using reference standards or radiolabeled compounds Chem. Res. Toxicol. 23, 1871-1873
29. Lappin, G., Seymor, M., Gross, G., Jorgensen, M., Kall, M., and Kvaerno, L. (2012) Meeting the MIST regulations: human metabolism in Phase I using AMS and a tiered bioanalytical approach Bioanalysis 4, 407-416
30. Luffer-Atlas, D. (2012) The early estimation of circulating drug metabolites in humans Expert Opin. Drug Metab. Toxicol 8, 985-997
31. Loi, C.-M., Smith, D. R., and Dalvie, D. (2013) Which metabolites circulates? Drug Metab. Dispos. 41, 933-951
32. Timmerman, P., Kall, M. A., Gordon, B., Lakso, S., Freisleben, A., and Hucker, R. (2010) Best practices in a tiered approach to metabolite quantification: Views and recommendations of the European Bioanalysis Forum Bioanalysis 2, 1185-1194
33. Garafolo, F., Savoie, N., Bergeron, A., Amestoy, C., Lefebvre, M., Caille, L., Furtado, M., and Menard, C. (2010) Importance of metabolite testing in regulatory bioanalysis Bioanalysis 2, 1171-1174
34. Isin, E. M., Elmore, C. S., Nilsson, G. N., Thompson, R. A., and Weidolf, L. (2012) Use of radiolabeled compounds in drug metabolism and pharmacokinetic studies Chem. Res. Toxicol. 25, 532-542
35. Neddermann, A. N. R., Dear, G. J., North, S., Obach, R. S., and Higton, D. (2011) From definition to implementation: a cross-industry perspective of past, current and future MIST strategies Xenobiotica 41, 605-622
36. Hamilton, R. A., Garnett, W. R., and Kline, B. J. (1981) Determination of mean valproic acid serum level by assay of a single pooled sample Clin. Pharmacol. Ther. 29, 408-413
37. Ramanathan, R., Josephs, J. L., Jemal, M., Arnold, M., and Humpreys, W. G. (2010) Novel MS solutions inspired by MIST Bioanalysis 2, 1291-1313
38. Briscoe, C. J. and Hage, D. S. (2009) Factors affecting the stability of drugs and drug metabolites in biological matrices Bioanalysis 1, 205-220
39. Spreadborough, M. J., Day, J., Jackson-Addie, K., and Wilson, A. (2013) Bioanalytical implementation of plasma capillary microsampling: small hurdles, large gains Bioanalysis 5, 1485-1489
40. Arlander, E., Ekström, G., Alm, C., Carrillo, J. A., Bielenstein, M., Böttiger, Y., Bertilsson, L., and Gustafsson, L. L. (1998) Metabolism of ropivacaine in humans is mediated by CYP1A1 and to a minor extent by CYP3A4: An interaction study with fluvoxamine and ketoconazole as in vivo inhibitors Clin. Pharmacol. Ther. 64, 484-491
41. Burm, A. G. L., Stienstra, R., Brouwer, R. P., Emanuelsson, B.-M., and van Kleef, J. W. (2000) Epidural infusion of ropivacaine for postoperative analgesia after major orthopedic surgery Anesthesiology 93, 395-403
42. Bruguerolle, B., Attolini, L., and Gantenbein, M. (1994) Acute toxicity of bupivacaine metabolites in mice Clin. Exp. Pharmacol. Physiol. 21, 997-999
43. Prueksaritanont, T., Lin, J. H., and Baillie, T. A. (2006) Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites Toxicol. Appl. Pharmacol. 217, 143-152
44. Obach, R. S., Nedderman, A. N., and Smith, D. A. (2012) Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary? Xenobiotica 42, 46-56
45. Prakash, C., Li, Z., Orlandi, C., and Klunk, L. (2012) Assessment of exposure of metabolites in preclinical species and humans at steady state from the single-dose radiolabeled absorption, distribution, metabolism, and excretion studies: A case study Drug Metab. Dispos. 40, 1308-1320
46. White, R. E., Evans, D. C., Hop, C. E. C. A., Moore, D. J., Chandra Prakash, C., Surapaneni, S., and Francis L. S. Tse, F. L. S. (2013) Radiolabeled mass-balance excretion and metabolism studies in laboratory animals: a commentary on why they are still necessary Xenobiotica 43, 219-225
47. Dueker, S. R., Lohstroh, P. N., Giacomo, J. A., Vuong, L. T., Deck, B. D., and Vogel, J. S. (2010) Early human ADME using microdoses and microtracers: bioanalytical considerations Bioanalysis 2, 441-454